EX-99.1 2 brkr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bruker Reports Fourth Quarter and Full Year 2025 Financial Results • Q4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically • Q4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS of $0.59 • FY25 revenues of $3.44 billion, up ~2% yoy, down ~4% organically • FY25 GAAP diluted loss per share of $(0.15); non-GAAP diluted EPS of $1.83 • Bruker initiates FY26 guidance: o Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% o Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind BILLERICA, Massachusetts - February 12, 2026 - Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker’s President and CEO, commented: “At the conclusion of a difficult year 2025, with headwinds from academic funding, tariffs and currencies, we are pleased that in the fourth quarter we delivered revenues ahead of our expectations. A recovery in biopharma and industrial research markets in the second half of the year, as well improvem…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Bruker Corporation
BRKRNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 12, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three months and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.…
Company context
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in specialty diagnostics, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, clinical microbiology and molecular diagnostics, as well as in the semiconductor industry. For more information, please visit www.bruker.com.